Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
Sumitomo Dainippon Pharma saw its group revenue inch down 1.6% to 459,267 million yen in the year ended March 2019 as drug price cuts and generic encroachments dealt a blow to its Japan business, according to its earnings released on…
To read the full story
Related Article
- Sumitomo Dainippon Ekes Out Quarterly Growth as North America Sales Offset Japan Dip
July 30, 2019
- Sunovion to Push Different Dasotraline Trial Data in FDA Negotiations: Sumitomo Dainippon Chief
May 13, 2019
- Sumitomo Dainippon Cuts Sales Outlook for FY2018, Ups Profit Forecast
April 22, 2019
- Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
- Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
- Tanabe Starts Long-Term Uplizna Study in IgG4-Related Disease
June 25, 2026
- ASKA Shareholders Back Faster Poison Pill Activation
June 25, 2026
- EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
- Tacrolimus Generics Add Cell Transplantation Indication
June 25, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…